C16
PKR kinase inhibitor
Product Specifications
Background
C16 is a derivative of imidazolo-oxindole and inhibits RNA-dependent protein kinases (PKR). Its inhibition effect on PKR is ATP-binding site directed. C16 has been shown to specifically inhibit the apoptotic PKR/eIF2a signaling pathway.
CAS Number
608512-97-6
Product Name Alternative
Imidazolo-oxindole PKR inhibitor C16, 6,8-Dihydro-8- (1H-imidazol-5-ylmethylene) -7H-pyrrolo[2,3-g]benzothiazol-7-one
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cell Signaling | Cancer | Apoptosis | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors
Purity
≥98% (HPLC)
Weight
0.005
Format
Solid
Solubility
Soluble in DMSO 12 mg/ml
Molecular Formula
C13H8N4OS
Molecular Weight
268.3
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Couturier J., et al. (2010) J. Biol. Chem. 285(2): 1272–1282.
2. Jammi N.V., Whitby L.R., & Beal P.A. (2003) Biochem. Biophys.Res. Comm. 308(1):50–57.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ELI-46987h 96 Tests
Human Uncharacterized protein C16orf45, C16orf45 ELISA KIT
Sign In for Pricing
View Details 
325840-01 50 µL
IkB-alpha (NFKBIA, IKBA, MAD3, NFKBI, NF-kappa-B Inhibitor alpha, I-kappa-B-alpha, IkB-alpha, IkappaBalpha, Major histocompatibility complex enhancer-binding protein MAD3)
Sign In for Pricing
View Details 325840-02 100 µL
IkB-alpha (NFKBIA, IKBA, MAD3, NFKBI, NF-kappa-B Inhibitor alpha, I-kappa-B-alpha, IkB-alpha, IkappaBalpha, Major histocompatibility complex enhancer-binding protein MAD3)
Sign In for Pricing
View Details 